Operator of a pathology therapeutic selection platform intended to detect genomic biomarkers and make access to possible treatments. The company's platform specializes in providing cancer diagnosis, new targets for cancer treatment, and new therapeutic approaches, enabling researchers to make cancer detection and care more equitable around the globe.

Operator of a US-based data science company intended to leverage data analysis for impactful life science and drug discovery insights. The company offers expert data analysis in bioinformatics, genomics, and AI, unlocking hidden patterns and trends within complex biological datasets, enabling customers to make informed decisions in drug discovery, biomarker identification, and genomic analysis.

My Next Health builds health applications that provide insights into the prevention and treatment of chronic diseases using a novel approach to functional genomics. These applications allow consumers to self-manage those insights based on their own genetic predispositions, and can help inform their healthcare providers on interventions.

DNAlytics develops innovative data-driven precision medicine solutions (diagnosis, prognosis, treatment guidance) through partnerships with healthcare players such as pharmaceutical, biotechnological or In Vitro Diagnostic (IVD) companies. DNAlytics wants its solutions to have a major impact on patients, healthcare practitioners and Society as a whole. DNAlytics is a Belgian company founded in 2012 as a UCLouvain Spin-Off that bases its activities on a data mining technology platform. Aside from product (co)development, DNAlytics also proposes its expertise in the form of a data mining consultancy service. In this context we serve various types of customers. DNAlytics received various awards, namely from IBM, Microsoft, the European Commission or the MIT, both for its technology and its business model.

Genuity Science provides clinco-omics data analysis solutions for researchers. They also provide genomic sequence data. Their platform offers study design, sequencing, storage, interpretation, secondary analysis, and scalable analytics, enabling organizations to improve patient health using the human genome.

PersMed Co., working on analyzing genomic data, with a specific focus on cancer, we are contributing to a field that has the potential to make a significant impact on healthcare. With the increasing availability of genomic data, we are able to study the underlying genetic causes of cancer in unprecedented detail, opening up new possibilities for the development of more effective treatments and prevention strategies. Our work involves analyzing large amounts of genomic data to identify patterns and anomalies that may be associated with cancer. By applying advanced statistical and machine learning techniques to this data, we can uncover important insights into the molecular mechanisms underlying cancer development and progression. Your research has the potential to lead to the development of new diagnostic tools and targeted therapies that can improve patient outcomes and quality of life. By understanding the genetic basis of cancer, we can develop more precise and personalized treatment options that are tailored to each patient's unique genetic profile. Overall, our work in analyzing genomic data for cancer research is an important contribution to the field of healthcare. With our expertise in data analysis and genomics, we are well-positioned to make significant contributions to the development of new cancer treatments and prevention strategies that can improve the lives of millions of people around the world.

StoneWise, founded in 2018, is a technology company committed to accelerating novel drug discovery with artificial intelligence. We intend to use AI technology and innovation to lead a paradigm shift in Drug discovery for the pharmaceutical industry. Our goal is to replace the previous single-engine drug R&D focusing onexperts based model with the new twin-engine drug R&D model with advanced AI technology and expert system. Our platform is designed by cutting-edge technologies such as artificial intelligence and microfluidics, integrated with computational chemistry, computational biology, pharmacology and clinical medicine. The Platform provides pharmaceutical companies with integrated solutions.These solutions include a vast range of tools such as medical knowledge graph,the discovery of priviledged scaffolds,molecular generation and design,as well as predicting reaction products and planning path synthesis.Using this platform,StoneWise hopes to enhancing the efficiency and success rate of early stage drug discovery. StoneWise has engaged a number of domestic and foreign technical experts in the field of Internet, artificial intelligence, pharmaceutical industry and other scientific disciplines. It equips a state of art scientific drug discovery facility, keeps track of latest innovating in drug discovery, and provides its customers with excellent technologies, products and services. StoneWise started to collaborate with domestic and foreign universities, research institutions and pharmaceutical factories.

Our project develops a computerized (in silico) approach to optimise the efficacy and precision of drug repurposing trials. De novo drug design requires 10 to 15 years until market entry. We want to help patients faster and more efficiently. In comparison to de novo drug design, drug repurposing can happen much faster, costs less, and imposes a lower risk. The time for validation of a known drug’s potential new purpose is significantly reduced because less or no animal experiments are required, clinical studies can be conducted sooner, potential side effects are already known. So far, finding a new use for an old drug (drug repurposing) has been a serendipitous process. REPO-TRIAL aims to improve the efficacy and precision of predicting new purposes for registered drugs by using a revolutionary in silico approach. We use computer-based algorithms and an innovative definition of diseases to screen for potentially beneficial effects of registered drugs in mechanistically related disease phenotypes. We then validate promising in silico-repurposed candidate drugs up to the clinical level. The algorithms that we use to identify mechanistically related disease phenotypes may include completely different organs or areas of the human body than the original was used for. This systems-based (integrative / whole-body) approach will create “virtual patient cohorts”. Finally, we will validate in silico repurposed drugs in actual clinical studies with real patients and high precision. Because validation of all new drug repurposing opportunities would be unrealistic, we will focus on a patient cohort that the REPO-TRIAL consortium understands very well (a) metabolic and cerebrocardiovascular disease phenotypes, such as stroke, diabetes or Alzheimer’s, or b) patients that are positive for a specific panel of diagnostic blood biomarkers that can be measured in the laboratory). REPO-TRIAL will provide rapid patient benefits, reduce drug development time & costs, and reduce risks.

Acutis Biosciences is a subsidiary Contract Research Organization (CRO) under the ownership of Acutis. At Acutis Biosciences, we are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics, and rewriting the rules to champion our biopharma partners. Our focus isn't just pioneering drug discovery and development; it's also forging an era of service excellence, setting a new standard in the industry to elevate precision medicine to another level. We specialize in enabling biopharmaceutical companies to discover biomarkers through advanced multi-omics analysis solutions powered by machine learning (ML) and artificial intelligence (AI). Our technology platforms in genomics and histopathology support our partners in development and validation of state-of-the-art cancer molecular diagnostic assays, in oncology, immuno-oncology and infectious diseases. Leading pharmaceutical and biotech companies trust us to deliver 11-star service coupled to extraordinary science. Learn more: www.acutisbiosciences.com

e-NIOS develops a platform for unsupervised analysis and interpretation of Genomics data of multiple sources (multi -omics), with applications in Biotechnology, Drug Discovery and Personalized Medicine.